DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of ...
Four immunoassays for neurofilament light chain (NfL) demonstrate consistent performance in patients with amyotrophic lateral ...
18h
StudyFinds on MSNBreakthrough blood test could transform ALS diagnosis, careFind out about the new ALS blood test that offers accurate diagnosis and could replace traditional invasive testing methods.
The experts say if you notice that you produce a "lot of saliva (drool)", then this could indicate motor neurone disease (MND ...
ALS, or amyotrophic lateral sclerosis, can sometimes be difficult to diagnose or to predict how quickly the disease is likely to progress. A new study helps determine which blood tests are best at ...
Experts warn that excessive saliva, or drooling, could be a potential indicator of motor neurone disease (MND), a condition ...
A blood test can help doctors detect ALS, or amyotrophic lateral sclerosis, and predict how the degenerative disease will ...
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solutions ...
21h
News Medical on MSNStress granules as potential biomarkers for neurodegenerative diseasesStress granules (SGs) are transient organelles that form when cells experience stress, serving as critical hubs for RNA metabolism and cellular survival.
Tetramethylpyrazine nitrone is safe for ALS and may slow grip strength decline, especially in younger patients.
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)On-track to enable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results